AORT

CryoLife, Inc. (ARTIVION, INC.) 10-Q Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2002. CryoLife, Inc. is a medical device and services company specializing in human tissue preservation services and implantable medical devices. The filing is significantly impacted by a subsequent event: an FDA Order received on August 13, 2002, mandating the recall and retention of non-valved cardiac, vascular, and orthopaedic tissues processed since October 3, 2001, due to alleged violations of 21 CFR Part 1270 regarding contamination prevention.

The Company also changed independent auditors during the period, dismissing Arthur Andersen LLP and appointing Deloitte & Touche LLP.

Key Financial Metrics (Six Months Ended June 30, 2002)

Note: Financial results for the quarter ended June 30, 2002, were adjusted to reflect the FDA Order as a Type I subsequent event, resulting in a $12.6 million reduction to pretax income.

Material Changes vs. Prior Period

• Revenue Composition: While total revenue increased 13% year-over-year, this growth was masked by a $2.4 million revenue reduction due to estimated tissue returns from the FDA recall. Excluding the recall, revenue would have increased 19%.
• Profitability Collapse: The Company swung from a net income of $4.5 million in the prior year to a net loss of $2.4 million. This was driven primarily by a $10.0 million write-down of deferred preservation costs for tissues subject to the FDA Order.
• Cost Structure: Cost of human tissue preservation services surged to $25.3 million (67% of revenue) compared to $15.4 million (41% of revenue) in the prior year, largely due to the asset impairment.
• Product Growth: BioGlue Surgical Adhesive revenues doubled to $10.1 million, representing 21% of total revenue, driven by FDA approval in late 2001.

Guidance, Outlook, and Risks

Management Commentary & Outlook: Management anticipates a significant decrease in liquidity and revenues for the remainder of 2002. The Company expects to record further write-downs in the third quarter, including approximately $3.9 million for tissues processed in Q3 and a substantial write-down for orthopaedic tissues not subject to the initial order but impacted by adverse publicity. To preserve cash, the Company announced a reduction of approximately 105 employees, expecting monthly personnel cost savings of $360,000. Management believes current resources will meet liquidity needs through June 30, 2003, but may require additional financing thereafter.

Material Risks & Contingencies:

• FDA Order Impact: 78% of revenue comes from tissue preservation, and 67% of that ($26.9 million) is from tissues subject to the recall. Even if the order is lifted, demand may not return due to adverse publicity.
• Debt Default: The lender has determined the FDA Order and SEC inquiry constitute an "event of default" under the Term Loan. While the lender has not declared default as of August 30, 2002, it reserves the right to do so. A new $10 million line of credit was established but advances are currently restricted due to non-compliance.
• SEC Investigation: The Company is under an informal SEC investigation regarding the FDA Order announcement and potential securities law violations.
• Litigation: Fifteen product liability cases are pending, and several putative class-action lawsuits allege securities fraud. The Company has accrued $1.2 million for insurance deductibles.
• Delisting Risk: Due to the FDA Order and stock price volatility, there is a risk of delisting from the New York Stock Exchange.

Investor Verification Checklist

• FDA Appeal Status: Verify the outcome of the Company's appeal and request for modification of the FDA Order, specifically regarding life-saving cardiac and vascular tissues.
• Debt Covenant Compliance: Confirm whether the lender has formally declared an event of default on the Term Loan or restricted the new line of credit further.
• Third-Quarter Write-downs: Monitor Q3 2002 filings for the anticipated additional write-downs of orthopaedic tissue costs and Q3 processed tissue costs.
• SEC Investigation Progress: Track any updates regarding the scope and findings of the SEC investigation into the Company's disclosures.
• Liquidity Runway: Assess whether the Company can meet its liquidity needs through mid-2003 without raising additional capital, given the suspension of tissue shipments.